Hema Now | Episode 21
In this episode, Jonathan Sackier welcomes Claudio Cerchione, Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology.
Apple | Amazon Music | YouTube | Download MP3 (32 mins)
Claudio Cerchione
Claudio Cerchione is a haematologist and researcher at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. He specialises in multiple myeloma, amyloidosis, and other plasma cell disorders, and has contributed to numerous national and international clinical trials. His work focuses on advancing personalised treatment strategies and improving outcomes through innovative, patient-tailored care.
Timestamps
2:14 Memorable career experiences for Claudio
4:20 Biggest breakthrough in MM
5:10 Interest in plasma cell disorders
6:30 A surprising fact about multiple myeloma
7:40 Claudio’s top choice for a dinner party guest
10:30 The importance of MRD in haematology
13:00 Monoclonal antibodies and CAR-T therapies
19:00 Current challenges
22:22 Claudio’s key EHA and ASCO takeaways
28:30 Claudio’s three magic wishes
The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
